Methods of treatment by administering an anti-BAFFR antibody therapeutic formulation

A method of treating an autoimmune disease in a patient in need thereof comprising the step of administering to said patient an aqueous composition having a pH of 6.0 and comprising:

• a hypofucosylated or non-fucosylated anti-B-cell Activating Factor Receptor (BAFFR) antibody wherein the antibody has a concentration of 150 mg/mL and wherein said anti-BAFFR antibody comprise heavy chain CDR1, CDR2 and CDR3 of SEQ ID NOs:
• 3, 4 and 5 respectively, and light chain CDR1, CDR2 and CDR3 of SEQ ID NOs:
• 6, 7 and 8, and:
• (a) (i) 220 mM sucrose as a stabilizer,
• (ii) 20 mM histidine as a buffering agent,
• (iii) 0.04% polysorbate 20 as a surfactant;
• or
• (b) (i) 220 mM trehalose as a stabilizer,
• (ii) 20 mM histidine as a buffering agent,
• (iii) 0.04% polysorbate 20 as a surfactant;
• or
• (c) (i) 120 mM sucrose as a stabilizer,
• (ii) 20 mM histidine as a buffering agent,
• (iii) 0.04% polysorbate 20 as a surfactant, and
• (iv) 50 mM arginine.